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Abstract
Background: The artificial colloid, hydroxyethyl starch (HES), is recommended for intravascular volume expansion
and colloid-osmotic pressure enhancement in dogs and cats. A well-known side effect of HES solutions in humans
and dogs is coagulopathy. However, HES-associated coagulopathy has thus far not been investigated in cats. The
goal of this study was to assess the in vitro effects of 6 % HES 130/0.42 on feline whole blood samples using
rotational thromboelastometry (ROTEM). A further goal was to develop feline reference intervals for ROTEM at our
institution. In this in vitro experimental study, blood samples of 24 adult healthy cats were collected by atraumatic
jugular phlebotomy following intramuscular sedation. Baseline ROTEM analyses (using ex-tem, in-tem and fib-tem
assays) were performed in duplicate. Additionally, ROTEM analyses were performed on blood samples after dilution
with either Ringer’s acetate (RA) or 6 % HES 130/0.42 (HES) in a 1:6 dilution (i.e. 1 part solution and 6 parts blood).
Results: Coefficients of variation of duplicate measures were below 12 % in all ex-tem assays, 3 of 4 in-tem assays
but only 1 of 3 fib-tem assays. Reference intervals were similar albeit somewhat narrower than those previously
published. Dilution with both solutions lead to significantly prolonged CT (in-tem), CFT (ex-tem and in-tem), and
reduced MCF (ex-tem, in-tem, and fib-tem) and alpha (ex-tem and in-tem). Compared to RA, dilution with HES
caused a significant prolongation of CT in fib-tem (P = 0.016), CFT in ex-tem (P = 0.017) and in-tem (P = 0.019), as
well as a reduction in MCF in in-tem (P = 0.032) and fib-tem (P = 0.020), and alpha in ex-tem (P = 0.014). However,
only a single parameter (CFT in ex-tem) was outside of the established reference interval after dilution with HES.
Conclusions: In vitro hemodilution of feline blood with RA and HES causes a small but significant impairment of
whole blood coagulation, with HES leading to a significantly greater effect on coagulation than RA. Further studies
are necessary to evaluate the in vivo effects and the clinical significance of these findings.
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Background
The artificial colloid, hydroxyethyl starch (HES), is rec-
ommended for the treatment of anesthesia-induced
hypotension, for resuscitation and to increase colloid-
osmotic pressure in cats [1, 2]. Although various doses
have been recommended [3, 4], no study has thus far
evaluated the side effects of HES solutions or established
safe doses in cats.
Until recently, HES was widely used in human inten-
sive care units throughout the world and was considered
the artificial colloid of choice for resuscitation, especially
in Europe [5]. The physicochemical properties of mod-
ern, third generation HES solutions (i.e. HES 130/0.4
and HES 130/0.42) were aimed to improve its safety pro-
file and minimize adverse effects, such as kidney injury,
tissue storage, and coagulopathy [3, 4]. However, results
of recent clinical trials showed risks related to kidney
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dysfunction, hemorrhage, and increased mortality in sep-
tic and critically-ill human patients [6–8]. As a result,
the use of HES in humans has been restricted by inter-
national authorities [9]. As little data is available with
regards to safety in small animals, questions regarding
the use of various HES solutions in veterinary medicine
have arisen [3, 10].
The pathophysiology of hemostatic effects of HES is
well described in several human and veterinary medical
reviews [4, 11]. Indirect effects, due to hemodilution, as
well as direct effects of HES molecules on components
of the hemostatic system lead to an increased risk for
hemorrhage [11–13]. Recent canine studies revealed a
dose-dependent impairment of coagulation and platelet
function with different HES products [14–18]. However,
no data evaluating the effects of HES on feline hemostasis
have thus far been published.
Assessment of whole blood coagulation using rota-
tional thromboelastometry (ROTEM) has previously
been evaluated in dogs and reference intervals have been
established [19]. In addition, the effects of tetrastarch so-
lutions on canine whole blood coagulation have been
evaluated [15, 18, 20]. In cats, rare studies have been
performed evaluating whole blood coagulation using
thromboelastography [21–25] and recently, one study,
assessing reference intervals in healthy cats using
ROTEM was published [26]. To the authors’ knowledge,
the effects of isotonic crystalloids or HES on feline
whole blood coagulation using ROTEM have not been
previously evaluated.
The objective of the present study was to assess the
in vitro effects of HES 130/0.42 compared to isotonic
crystalloids on ROTEM analyses in feline blood. The
hypothesis was that both solutions cause impairment of
whole blood coagulation due to hemodilution and that
HES would impair coagulation to a greater extent than
crystalloids. A secondary objective was to develop




The study protocol was approved by University of Bern
and the Animal Experiment Committee of the Swiss
Federal Veterinary Office (No. 37/14). Informed owner
consent was obtained before study enrollment. Thirty-
four staff-owned cats with a minimum body weight of
3 kg and an age between 1 and 12 years old were initially
enrolled in the study. Cats were included if they were
deemed healthy based on history, clinical examination,
unremarkable results of a CBC (Advia® 120, Siemens
Healthcare Diagnostics AG, Zurich, Switzerland), biochem-
istry panel (Cobas® c501, Roche Diagnostics, Rotkreuz,
Switzerland), and standard coagulation profile (STart 4
Hemostatis Analyzer ®, Stago CH SA, Zurich, Switzerland),
including prothrombin, activated partial thromboplastin
and thrombin times, and fibrinogen using the Clauss
method, as well as negative results for feline immunodefi-
ciency virus and feline leukemia virus ELISA tests (SNAP®
Combo Plus FIV/FeLV, IDEXX Europe, Hoofddorp,
Netherlands). In addition, cats were excluded if evidence of
cardiomyopathy was detected using two-dimensional and
M-mode echocardiographic examination, performed by a
board-certified veterinary cardiologist (AK). Cats were also
excluded if they had received any medication or vaccina-
tions, or infusions with synthetic colloids or blood prod-
ucts within 4 weeks prior to study enrollment.
Study fluids
The HES product used in this study was a potato-
derived HES with a molecular weight of 130 kDa and a
molar substitution of 0.42 in a concentration of 60 g/L
(6 % solution) in an electrolyte-balanced and buffered
carrier solution (Tetraspan®, BBraun Melsungen AG,
Melsungen, Germany). The crystalloid was a modified
Ringer’s acetate (RA) solution (Ringerfundin®, BBraun
Melsungen AG, Melsungen, Germany).
Rotational thromboelastometry
Three four-channel ROTEM (ROTEM®, TEM Innova-
tions GmbH, Munich, Germany) analyzers were used to
assess whole blood coagulation. The method dynamically
analyses the viscoelastic properties of blood during initi-
ation and propagation of clotting, as well as during fi-
brinolysis and is described in detail elsewhere [27].
Recalcification was performed using the calcium chlor-
ide reagent provided by the manufacturer (star-tem®,
Tem International GmbH, Munich, Germany). Activat-
ing reagents used were ex-tem (ex-tem®, Tem Inter-
national GmbH, Munich, Germany), which triggers the
extrinsic pathway using tissue factor, in-tem (in-tem®,
Tem International GmbH, Munich, Germany), which
triggers contact activation using ellagic acid, and fib-tem
(fib-tem®, Tem International GmbH, Munich, Germany),
which triggers the extrinsic pathway with platelet inhib-
ition using cytochalasin D. Data obtained from the
ROTEM analyzers were clotting time (CT, the time from
activation until the onset of clotting), clot formation
time (CFT, time between the onset of clotting and clot
firmness with an amplitude of 20 mm) (in-tem and ex-
tem only), maximum clot firmness (MCF, maximum amp-
litude of the curve) and alpha (α, slope of the tangent).
Blood sampling procedure
Cats were sedated by intramuscular injection of 0.3 mg/
kg butorphanol (Morphasol® 10, Dr. E. Graeub AG, Bern,
Switzerland), 2 mg/kg ketamine (Ketasol 100®, Dr. E.
Graeub AG, Bern, Switzerland) and 0.2 mg/kg midazolam
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(Dormicum®, Roche Pharma Schweiz AG, Reinach,
Switzerland). Blood was sampled by atraumatic phlebot-
omy of the jugular vein using a 21G butterfly needle. An
initial 1.5 ml of blood was collected using a syringe at-
tached to the butterfly needle in EDTA and heparin tubes
(for CBC and biochemistry), followed by connection to a
vacutainer system (BD Vacutainer® Push Button blood col-
lection set, 21 G butterfly needle BD, Plymouth, United
Kingdom) and filling of three 1.8 ml citrate tubes (BD
Vacutainer® 1.8 ml coagulation tube, buffered trisodium
citrate 3.2 %, BD, Plymouth, United Kingdom) for coagu-
lation profiles and ROTEM analyses.
Dilutions and measurements
After a resting period of 15 min, baseline ROTEM mea-
surements to establish reference intervals were per-
formed in duplicate. The remaining citrated blood was
diluted 1:6 (1 part study fluid and 6 parts blood) with
RA and HES, respectively. The appropriate amount of
blood was filled in prewarmed polypropylene tubes con-
taining either HES or RA with a pipette. Mixing was
performed by careful inverting and rolling the tube 6
times, followed by 5 min’ incubation. The dilution was
selected to simulate a bolus administration of 10 ml/kg,
taking into account a blood volume of approximately
62–66 ml/kg body weight in an adult cat [28]. Three
ROTEM devices were used in parallel and all measure-
ments were started within 60 min after blood sampling.
Samples for ROTEM measurements were stored at 37 °C
in a thermostatic tube heater (WiseTerm Heating Block
R48®; WITEG Labortechnik GmbH, Wertheim, Germany)
and analyses were performed according to the manufac-
turer’s instructions. Run time was preset to 60 min. As
blood collection and sample handling was shown to sig-
nificantly affect whole blood coagulation in dogs [19], a
single investigator (NAA) collected all samples and run all
ROTEM analyses.
Statistical analysis
Data were assessed for normality using Q-Q plots and
D’Agostino-Pearson tests. As some ROTEM data were
normally distributed but others were not and could not
be transformed to normality, nonparametric analyses
were performed. A Friedman test was used to assess dif-
ferences between samples. Where significant differences
were found, a post-hoc analysis was performed using
Wilcoxon paired-samples tests with Bonferroni correc-
tion. The coefficient of variation of baseline duplicate
measurements was calculated. Double-sided reference
intervals were determined based on the average of the
two repeated baseline values, using the robust method
(CLSI guideline C28-A3) with confidence intervals esti-
mated by bootstrapping. All statistical analyses were per-
formed using commercial software (MedCalc Software®
version 14.10, Ostend, Belgium) and significance was set
at P < 0.05 throughout.
Results
Of the 34 cats initially enrolled, ten cats were excluded
due abnormal results of echocardiographic examinations
(n = 4), anemia (n = 1), increased plasma creatinine con-
centrations (n = 1), prolonged prothrombin time (n = 1),
thrombocytopenia (n = 1), and decreased fibrinogen
levels (n = 1). Only data from the remaining 24 cats were
included in analyses. These were domestic shorthair cats
(n = 22) and Bengal cats (n = 2). The cats had a mean
age of 4.5 years (range, 1.5–11.2 years) and a mean body
weight of 4.5 kg (range, 3.0–6.4 kg). Twelve cats were
male (1 sexually intact, 11 castrated) and 12 were female
(all spayed).
Hematologic variables
The mean (±SD) of hematologic variables included
hematocrit, 31 ± 5 % (0.31 ± 0.05 L/L); platelet count,
267 ± 79 × 109/L; prothrombin time, 11.2 ± 0.6 s; activated
partial thromboplastin time, 12.4 ± 1.2 s; and thrombin
time, 16.9 ± 1.8 s. The median (range) of fibrinogen con-
centrations was 143 (102–294) mg/dL.
Reference intervals
Reference intervals were evaluated after exclusion of the
two Bengal cats. These showed considerable intra-
individual variation. In particular, over a four-fold differ-
ence from the lower to upper reference interval was ob-
served for in-tem CFT and fib-tem MCF (Table 1).
Coefficients of variation (CV) of duplicate measures
Table 1 Reference intervals for ROTEM assays in 22 cats
Assay Interval CT (s) CFT (s) MCF (mm) Alpha (°)
ex-tem® lower (90 % CI) 35 (31–41) 38 (34–44) 62 (59–64) 74 (73–76)
upper (90 % CI) 71 (64–76) 78 (71–83) 74 (72–75) 82 (81–83)
in-tem® lower (90 % CI) 107 (87–130) 23 (12–33) 52 (46–58) 70 (67–74)
upper (90 % CI) 221 (197–244) 90 (77–101) 82 (76–86) 87 (83–90)
fib-tem® lower (90 % CI) 38 (34–43) n/a 5 (2–9) 52 (48–56)
upper (90 % CI) 66 (62–70) n/a 25 (22–24) 81 (76–85)
90 % CI 90 % confidence interval, n/a not applicable
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were generally below 12 %. However, CFT in in-tem
(CV, 24.2 %) and both CT (CV, 15.3 %) and MCF (CV,
20.6 %) in fib-tem showed larger imprecision (Table 2).
Dilution with ringer’s acetate and HES
Significant differences were observed between baseline
ROTEM values and the samples diluted with RA or
HES (Table 3). The dilution with both solutions lead to
significantly prolonged CT in-tem (RA, P = 0.0006;
HES, P = 0.002), CFT ex-tem (RA, P = 0.0006; HES, P =
0.0003) and in-tem (RA, P = 0.015; HES, P = 0.0003), as
well as to reduced MCF ex-tem (RA and HES P =
0.0003), in-tem (RA and HES, P = 0.0003) and fib-tem
(RA and HES, P = 0.0003) and alpha ex-tem (RA, P =
0.0006; HES, P = 0.0003) and in-tem (RA, P = 0.017;
HES, P = 0.0003) compared to baseline (Table 3). In
addition, dilution with RA alone lead to a shortening of
CT ex-tem (P = 0.015).
Compared to RA, dilution with HES lead to prolonga-
tion of CT fib-tem (P = 0.016), CFT ex-tem (P = 0.017)
and in-tem (P = 0.019), as well as reduction of MCF in-
tem (P = 0.032) and fib-tem (P = 0.020), and alpha ex-
tem (P = 0.014).
Despite statistically significant differences in ROTEM
assays after dilution with study solutions, the median mea-
sured value was outside of the established reference range
only after dilution with HES in ex-tem CFT (Table 3).
Discussion
This study demonstrates that in vitro hemodilution of fe-
line blood with RA and HES affects whole blood coagula-
tion measured by ROTEM, with HES leading to a greater
hemostatic impairment than RA. These findings corrobor-
ate those reported in humans and in dogs [11, 15, 29].
After both solutions, ROTEM parameters showed a hypo-
coagulable pattern, characterized by a longer duration of
clot formation and propagation time (increased CFT and
decreased alpha), and lower clot stability and less stable
fibrin network (decreased MCF). However, the magnitude
of the observed changes was low, and only a single par-
ameter (CFT ex-tem) was outside of the reference
interval established after dilution with HES, suggesting
that findings may not be of clinical relevance. In a re-
cent study, evaluating the effects of HES 130/0.4 on
canine ROTEM parameters, 25 % dilution resulted in 7
of 13 parameters being outside the of reference inter-
vals although all parameters were within reference
limits after 10 % dilution [15]. In a similar study in dogs
with the same HES preparation, 25 % dilution resulted
in 4 out of 5, and 10 % dilution resulted in 2 out of 5
ROTEM parameters being significantly impaired com-
pared to the dilutional control with saline [18]. Several
reasons may be responsible for the smaller effects on
feline coagulation in the present study. Firstly, the dilu-
tion used was 1:6 (14 %) compared to 1:3 (25 %) in the
aforementioned canine studies. This likely resulted in
lesser coagulation impairing effects in the present
study. Moreover, feline platelets are more reactive than
those of other species, due to larger platelet size and
higher concentrations of serotonin [30]. Finally, the
HES preparation used in the present study was a
potato-derived starch in a calcium-containing carrier
solution, in contrast to the waxy-maize-derived starch
in calcium-free solution used in the aforementioned
canine studies. This might have influenced ROTEM
parameters, although only minor effects on coagula-
tion were found when comparing calcium-containing
versus calcium-free carrier HES preparations in a re-
cent in vivo study in dogs [20]. The reason why CFT
ex-tem was apparently affected more than other pa-
rameters following dilution with HES in the present
study is unclear, but similar findings were observed in
canine studies at low dilutions [15, 18]. Despite the
overall relatively minor effects observed, data in the
present study suggest that dilution with HES has a
more pronounced effect on whole blood coagulation
than RA, suggesting that effects of HES are beyond
that of dilution alone.
Table 2 Coefficients of variation (CV) of duplicate measure for
ROTEM assays in 22 cats
Assay CV (%)
CT CFT MCF Alpha
ex-tem® 8.95 7.96 4.72 2.08
in-tem® 11.95 24.20 3.38 2.92
fib-tem® 15.28 n/a 20.63 7.21
n/a not applicable
Table 3 ROTEM analyses in feline blood samples without
dilution (baseline), and samples diluted 1:6 with RA or HES
Assay Variable Baseline RA HES
ex-tem® CT (s) 52 (40–73) 48* (31–65) 52 (31–99)
CFT (s) 57 (44–77) 65* (44–123) ↑81*§ (61–146)
MCF (mm) 68 (60–74) 64* (53–71) 64* (56–69)
alpha (°) 78 (75–81) 76* (67–81) 74*§ (63–77)
in-tem® CT (s) 165 (131–246) 203* (153–303) 202* (154–282)
CFT (s) 54 (35–97) 67* (46–141) 73*§ (50–190)
MCF (mm) 68 (50–72) 62* (47–68) 60*§ (42–67)
alpha (°) 79 (72–83) 77* (63–80) 76* (66–80)
fib-tem® CT (s) 53 (37–62) 49 (30–65) 60§ (31–93)
MCF (mm) 15 (4–23) 9* (3–16) 8*§ (2–14)
alpha (°) 66 (54–77) 63 (47–75) 53 (43–62)
Values are expressed as median (range). * denotes a significant difference
(P < 0.05) between baseline and diluted samples; § denotes a significant
difference (P < 0.05) between samples diluted with HES and RA; ↑ denotes post-
dilution median values above the established reference interval
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Little data on ROTEM analyses in cats are currently
available. Notably, no data exist regarding the associ-
ation between ROTEM parameters and clinically rele-
vant impairment of hemostasis. Previous studies found
that cats with laboratory evidence of disseminated intra-
vascular coagulation rarely show clinical bleeding ten-
dencies [31, 32]. The observed changes in ROTEM
analysis after dilution with HES may therefore not be
of clinical significance at the dose simulated in the
current study.
Recently, feline reference intervals for ROTEM using
ex-tem and in-tem assays, based on 55 clinically healthy
European shorthair cats, were published [26]. Reference
ranges established in the present study were similar al-
though a narrower interval was found for some of the
parameters. However, reference intervals established in
the present assay were based on a smaller population,
and the robust method was used instead of a percentile
method. Intra-assay coefficients of variation, evaluated
from quadruplicate measurements, were found to be
below 10 % for CT, CFT, alpha, and MCF in a previous
study [26]. In another study, intra-assay CV was below
5 % in kaolin-activated thromboelastography in 30
healthy cats [24]. The coefficients of variation in our
study were below 10 % in 7 of the 11 ROTEM pa-
rameters, but were between 10 and 25 % in another 4
parameters. However, CVs established in the present
study were based on duplicate measurements in all 24
samples, but those previously published were based
on quadruplicate measurements in only two samples.
Moreover, although the mean of the 2 CVs was below
10 % in the previous study, the CV of one of the two
samples was above 10 % in 3 assays. Lastly, evalu-
ation of CVs using the fib-tem assay was not performed
in previous studies.
Although HES-associated coagulopathy may in part
be due to dilution alone, direct effects of HES on
hemostatic components have been observed [4, 11]. Of
these, an acquired impairment of fibrin polymerization is
suggested to be most important. A sensitive parameter
for monitoring fibrin polymerization with ROTEM is
MCF, in particular in the fib-tem assay. In the present
study, HES led to a significantly lower MCF compared
to RA in both the in-tem and fib-tem assays, but the
median value was still within the reference interval.
Impaired platelet function is another important aspect
of HES-induced coagulopathy. ROTEM parameters
which are influenced by both platelet numbers and
function are CFT, alpha, and MCF. A separate platelet
function analysis might have added more specific
information about the platelet impairing effect of HES
in cats.
As previous studies have demonstrated that cardiac
disease can affect coagulation in humans as well as in
cats and dogs [33–36], an attempt to exclude cats with
subclinical cardiomyopathy using echocardiography was
made in the present study. Indeed, one former study
evaluating the prevalence of cardiomyopathy in appar-
ently healthy cats identified cardiomyopathy in 16 % of
the cats [33]. Similarly, four of the originally enrolled 34
cats were excluded based on abnormal echocardiography
in the present study. As echocardiography was not per-
formed in the previous study reporting feline reference
intervals, the extent to which this may explain the wider
intervals previously reported is unclear. Unfortunately,
urinalysis was not performed in the present study as part
of the health assessment. Although plasma urea and cre-
atinine concentrations were within reference ranges,
early renal disease may have gone unnoticed. Further-
more, cats were not evaluated for hemotropic mycoplas-
mas or Cytauxzoon felis infection.
The study has some limitations. Firstly, all cats under-
went sedation to ensure atraumatic jugular venipuncture
and to harvest the required amount of blood for all ana-
lyses without interruption of blood flow. A previous
study in cats found that ketamine may slightly increase
prothrombin time and partial thromboplastin time after
intravenous administration in combination with diaze-
pam [37]. However, the observed changes were small
and likely not of clinical relevance [37]. Another study
showed differences in kaolin-activated thromboelasto-
graphic tracings between non-sedated cats and those
sedated with butorphanol and midazolam, with the latter
having a mild increase in the rapidity of clot formation
[24]. Neither reaction time nor maximum amplitude was
significantly affected in the sedated cats. Therefore, the
authors of that study suggested that the effects on
thromboelastographic variables may not be of major im-
portance. Due to the lack of studies using ROTEM in
cats, the extent to which prior sedation may have influ-
enced results in the present study is unclear. In addition,
ROTEM measurements were started after 15 min resting
time at 37 °C instead of 30 min at room temperature, as
recommended by the PROVETS guidelines [38]. This
was done in order to perform all analyses within 60 min
of blood collection and avoid temperature variations,
but may have affected results in some samples. Further-
more, the effects of transendothelial fluid shifts was ex-
cluded due to the in vitro character of the study. In
addition, vasoactive effects of fluids, endogenous release
of fibrinolytic factors, clot dissolution, excretion or deg-
radation of HES, and extraneous factors, such as stress
response, tissue damage, and endothelial injury are not
taken into account in an in vitro model. Results of the
current and other in vitro studies do not therefore
mimic in vivo conditions. A further limitation was the
dilution of citrated blood samples with citrate-free
study solutions, which may have resulted in an excess
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in calcium concentrations following the standardized
recalcification in the ROTEM cup. This in turn could
impact thrombin generation and diminished the hypo-
coagulable effects of HES. Finally, only healthy cats
were enrolled in this study, and the effects of fluid
therapy on coagulation may be more pronounced in
cats with pre-existing coagulopathies.
Conclusion
Data from the present study suggest that an in vitro 1:6
dilution with HES 130/0.42 affects feline whole blood
coagulation to a greater extent than a similar dilution with
RA. However, the magnitude of the observed changes was
small, and only a single parameter was outside of the
established reference interval after dilution with HES. Fur-
ther studies are necessary to evaluate the in vivo risk of
hemostasis impairment following administration of HES
in healthy cats and those with naturally occurring disease
and pre-existing coagulopathies.
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